|
Aug 15
|
Aptose Announces Adjournment of its Special Meeting of Shareholders
|
|
Jun 14
|
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
|
|
Jun 13
|
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Jun 3
|
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 3
|
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
May 31
|
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
May 31
|
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
May 14
|
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses
|
|
May 14
|
Aptose Reports Results for the First Quarter 2024
|
|
May 6
|
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
|
|
Apr 5
|
What Makes Aptose Biosciences (APTO) a New Buy Stock
|
|
Mar 27
|
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
|
|
Mar 26
|
Aptose Reports Results for the Fourth Quarter and Full Year 2023
|
|
Mar 18
|
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
|
|
Feb 5
|
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
|
|
Dec 9
|
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
|
|
Nov 30
|
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
|
|
Nov 2
|
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
|